Clinical trial enrollment in the presence of molecular tumor board: A broad demographic overview.

143 Background: Molecular Tumor Boards (MTB) encompass a multidisciplinary approach to applying the latest advances in molecular oncology to patient care. The Inova Schar Cancer Institute (ISCI) MTB meets weekly to review every patient’s next generation sequencing (NGS) results and make recommendations for clinical trial options whenever applicable. Methods: We conducted a retrospective chart review of patients reviewed by the ISCI MTB to investigate correlations between patient demographics and MTB-recommended clinical trial (CT) participation. Chi square analysis was performed, with hypotheses tested at a 5% significance level. Results: The ISCI MTB reviewed NGS reports from 4,732 patients between January 2016 and December 2024, 635 (13.4%) of whom subsequently enrolled in a therapeutic clinical trial and received at least one dose of study drug. Of 2,806 Caucasian patients, 416 (14.8%) enrolled in a clinical trial compared to 219 of 1,926 (11.4%) non-Black/African American patients experienced a CT enrollment rate of 8.4% (51/604), significantly lower than that of Caucasian patients (p<0.0001). In an analysis of language preferences recorded in the electronic medical record (EMR), 14.2% (574/4,026) of patients who preferred English and 10.3% (61/592) of patients who preferred a language other than English enrolled in a clinical trial. Conclusions: Approximately 13% of patients reviewed by the ISCI MTB enrolled in an interventional clinical trial. Non-Caucasian patients and those for whom English was not a preferred language were less likely to participate in a clinical trial. Clinical trial enrollment in an MTB patient population by diagnosis, race, and preferred language. ISCI MTB Clinical Trial Enrollment Diagnosis Race Preferred Language in EMR Breast 16.0% (68/425) American Indian or Alaska Native 9.1% (1/11)r English 14.3% (574/4,026) CNS 17.2% (34/198) Another race 13% (36/277) Non-English 8.6% (61/706) GI 14.6% (258/1,763) Asian (All) 12.7% (87/685) GU 11.6% (50/431) Black/African American 8.4% (51/604) GYN 13.5% (58/427) Hispanic/Latino 10.6% (17/161) Head and Neck 10.3% (14/136) Middle Eastern 19.4% (6/31) Lung 9.5% (76/798) Native Hawaiian or Other Pacific Islander 11.1% (1/9) Skin 16.3% (53/326) Other 21.4% (6/28) Thoracic 9.1% (3/33) White/Caucasian 14.8% (416/ 2,806) Other * 10.8% (21/195) More than one race 4.3% (1/23) Unavailable/unknown 14.6% (13/89) *Other consists of hematology, sarcoma, other, multiple primary and unknown malignancies.